Table 1.
Whole cohort and SID/EID groups characteristics.
| Variables** |
TOTAL
(n = 96) |
SID
(n = 71) |
EID (n = 25) | P-value* |
|---|---|---|---|---|
| Interval a-c duration (months) | 21 ± 12.2 | 11.7 ± 1.9 | 14.3 ± 3.4 | 0.003 |
| Age | 52.7 ± 9.2 | 53.1 ± 9.3 | 51.4 ± 9.2 | 0.432 |
| Female, n (%) | 54(56.3) | 42 (59.2) | 12(48) | 0.101 |
| Disease Duration (years) | 10.1 ± 8.5 | 10.5 ± 8.9 | 8.8 ± 6.9 | 0.337 |
| Naive, n (%) | 43 (44.8) | 32 (45.1) | 11 (44) | 0.724 |
| N. of DMTs before OCR | 1.2 ± 1.4 | 1.3 ± 1.4 | 1.1 ± 1.3 | 0.663 |
| EDSS before infusion a, median (IQR) | 6.0 (4.0-6.5) | 6.0 (4.0-6.0) | 6.0 (4.0-6.5) | 0.343 |
| Patients relapsing in the year before infusion a, n (%) | 12 (12.5) | 9 (12.6) | 3 (12) | 0.942 |
| Patients with MRI activity in the year before infusion a, n (%) | 17 (17.7) | 13 (18.3) | 4 (16) | 0.194 |
| Time on OCR (from starting to infusion a, months) | 30 ± 10.4 | 29.9 ± 10.6 | 32.9 ± 8.6 | 0.096 |
| Vaccination completed against Sars-Cov2, n (%) | 43(44.8) | 32 (45.1) | 11 (44) | 0.558 |
| CD19+ B cells depletion before Infusion a, n (%) | 56(58.3) | 43(60.6) | 13(52) | 0.487 |
| CD19+ B cells depletion before Infusion b, n (%) | 70(72.9) | 50(70.4) | 20(80) | 0.439 |
| CD19+ B cells depletion before Infusion c, n (%) | 65(67.7) | 49(69) | 16(64) | 0.630 |
Note: *via Anova with Welch correction and Chi-squared test/Fisher exact test; **data are reported as mean±standard deviation when otherwise specified.
Abbreviations: DMTs, disease modifying therapies; EID, extended interval dosing; EDSS, expanded disability status scale; MRI, magnetic resonance imaging; N. number; OCR, ocrelizumab; Sars-Cov2, severe acute respiratory syndrome coronavirus 2.